Skip to main content

Main menu

  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • Who we are
    • FAQ
    • Annual Report
  • Why New TB Drugs?
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Pipeline
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • Access in TB Market
    • Child-friendly medicines
    • Pretomanid and BPaL
    • Pathways to Access BPaL
  • News
    • Latest News
    • Publications
    • Voices of TB
    • Research Papers
    • Making an Impact
  • Donate

Search form

News Archive

March 18, 2012

ONLINE PRESS ROOM: NC-002 TRIAL LAUNCH

Trial Announcement Press Kit
March 18, 2012

TB Alliance Launches Combination Drug Trial, Establishes New Pathway to TB and MDR-TB Treatment

March 15, 2012

TB Alliance Launches Toolkit to Support TB R&D Advocacy

New Tools to Support the Development of New Tools
March 13, 2012

TB Alliance and Partners Awarded Grant from NIAID to Speed TB R&D

CTB2 Consortium gains funds to search for TB biomarkers
February 6, 2012

TB Alliance Appoints David Greeley, Head of External Affairs

Greeley to guide organization's resource mobilization and advocacy efforts to meet the needs of the growing TB drug pipeline
January 31, 2012

Statement from University College London on Completion of Enrollment in REMox TB

January 31, 2012

Statement from Kenya Medical Research Institute (KEMRI) Community Engagement Program on Completion of Enrollment in REMox TB

January 31, 2012

Statement from University of St Andrews on Completion of Enrollment in REMox TB

January 31, 2012

Statement from Bayer HealthCare on Completion of Enrollment in REMox TB

January 31, 2012

Statement from European and Developing Countries Clinical Trials Partnership (EDCTP) on Completion of Enrollment in REMox TB

Pages

  • «
  • ‹
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • …
  • ›
  • »

Navigate

  • About
  • Why New TB Drugs?
  • R&D
  • Access
  • News
  • Donate

New York: 80 Pine Street, 20th floor, New York, NY 10005 • +1 212 227 7540

Pretoria: Boardwalk Office Park, Block 1/Suite 5, 107 Haymeadow Street, Faerie Glen, Pretoria 0043, South Africa • +27 12 991 6328

Visit our South Africa website
Press Inquiries

Jess Wiggs
p | +1 646 616 8613
e | jessica.wiggs@tballiance.org

Jobs

View job openings

Join our mailing list
Interests
© 2023 The TB Alliance. All Rights Reserved. Site by Darby Communications Report a Concern